UA78696C2 - Novel compounds of sapogenin derivatives, use thereof and composition - Google Patents

Novel compounds of sapogenin derivatives, use thereof and composition Download PDF

Info

Publication number
UA78696C2
UA78696C2 UA2003108904A UA2003108904A UA78696C2 UA 78696 C2 UA78696 C2 UA 78696C2 UA 2003108904 A UA2003108904 A UA 2003108904A UA 2003108904 A UA2003108904 A UA 2003108904A UA 78696 C2 UA78696 C2 UA 78696C2
Authority
UA
Ukraine
Prior art keywords
group
compounds
епісарсасапогеніну
episarsasapogenin
pharmaceutically acceptable
Prior art date
Application number
UA2003108904A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of UA78696C2 publication Critical patent/UA78696C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UA2003108904A 2001-03-28 2002-03-28 Novel compounds of sapogenin derivatives, use thereof and composition UA78696C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0107822.9A GB0107822D0 (en) 2001-03-28 2001-03-28 Sapogenin derivatives their synthesis and use methods based upon their use
PCT/GB2002/001578 WO2002079221A2 (en) 2001-03-28 2002-03-28 Sapogenin derivatives, their synthesis and use

Publications (1)

Publication Number Publication Date
UA78696C2 true UA78696C2 (en) 2007-04-25

Family

ID=9911795

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003108904A UA78696C2 (en) 2001-03-28 2002-03-28 Novel compounds of sapogenin derivatives, use thereof and composition

Country Status (24)

Country Link
US (1) US20040147495A1 (pl)
EP (1) EP1383787B1 (pl)
JP (1) JP2004525945A (pl)
KR (1) KR20040007479A (pl)
CN (1) CN1678325A (pl)
AR (2) AR033079A1 (pl)
AT (1) ATE416185T1 (pl)
AU (1) AU2002242894B2 (pl)
BR (1) BR0208533A (pl)
CA (1) CA2442150A1 (pl)
CZ (1) CZ20032620A3 (pl)
GB (1) GB0107822D0 (pl)
HR (1) HRP20030770A2 (pl)
IL (1) IL158115A0 (pl)
MX (1) MXPA03008800A (pl)
NO (1) NO20034364L (pl)
NZ (1) NZ529136A (pl)
PE (1) PE20021042A1 (pl)
PL (1) PL364825A1 (pl)
RU (1) RU2311423C2 (pl)
TR (2) TR200301613T2 (pl)
UA (1) UA78696C2 (pl)
WO (1) WO2002079221A2 (pl)
ZA (2) ZA200307478B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
EP2111864A3 (en) * 2002-03-27 2009-12-30 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
NZ535093A (en) * 2002-03-27 2006-09-29 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
CA2503899C (en) * 2002-10-28 2011-12-20 Phytopharm Plc Stereospecific reduction of sapogen-3-ones
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
EP1618881A1 (en) * 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
GB0424528D0 (en) * 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
US20120034193A1 (en) 2009-01-24 2012-02-09 Daryl Rees Treatment of neurotrophic factor mediated disorders
CN101768202B (zh) * 2009-02-18 2013-10-30 沈阳药科大学 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途
US20130210786A1 (en) 2010-07-20 2013-08-15 Patrick Alexander Howson Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
TWI422378B (zh) * 2010-11-18 2014-01-11 Univ Chung Shan Medical 使用薯蕷皂素來改善與停經期症候群有關聯的認知缺陷
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
KR101480982B1 (ko) * 2013-03-20 2015-02-03 (주)셀인바이오 골형성 유도 화합물 및 이의 응용
CN104177469A (zh) * 2013-05-28 2014-12-03 江苏柯菲平医药有限公司 一种知母中菝葜皂苷元衍生物的制备方法
CN104324038B (zh) * 2013-07-24 2018-11-06 四川京华创生物科技有限公司 一种薯蓣皂苷元-3-位衍生物的用途
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319611T3 (pl) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
MX382122B (es) 2015-07-06 2025-03-13 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PT3519422T (pt) 2016-09-30 2022-12-05 Sage Therapeutics Inc Oxisteróis substituídos em c7 e métodos como moduladores nmda
DK4105223T3 (da) 2016-10-18 2025-07-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN109053854B (zh) * 2018-09-29 2021-05-14 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) * 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) * 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) * 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
JPS5855500A (ja) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
CA2073855C (en) * 1990-01-18 2007-04-24 Bill Elliot Cham Glycoalkaloids for controlling cellular autophagy
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
EP0647234A1 (en) * 1992-06-26 1995-04-12 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
CA2161239A1 (en) * 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl glycosidal crystalline monohydrate
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
EP0737202A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Hypocholesterolemic agents
EP0737203A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Steroidal glycosides
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
CA2198097A1 (en) * 1994-08-30 1996-03-07 Douglas J. Allen Spirostanyl glycosidal crystals
JPH09511753A (ja) * 1994-09-20 1997-11-25 ファイザー・インコーポレーテッド コレステロール吸収阻害薬とコレステロール合成阻害薬の併用
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
US6178679B1 (en) * 1996-02-13 2001-01-30 David M. Dundorf Weather-proof readerboard signage system
US5726179A (en) * 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
US5962445A (en) * 1996-05-09 1999-10-05 Amrad Operations Pty Ltd. Treatment of asthma and airway diseases
US5804239A (en) * 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
BR9909110A (pt) * 1998-03-26 2000-12-12 Phytopharm Plc Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives

Also Published As

Publication number Publication date
WO2002079221A3 (en) 2003-04-17
TR200301613T2 (tr) 2004-08-23
US20040147495A1 (en) 2004-07-29
HRP20030770A2 (en) 2005-08-31
NO20034364L (no) 2003-11-28
CZ20032620A3 (cs) 2004-04-14
NZ529136A (en) 2005-12-23
AR040402A1 (es) 2005-04-06
CA2442150A1 (en) 2002-10-10
JP2004525945A (ja) 2004-08-26
PE20021042A1 (es) 2002-11-19
EP1383787A2 (en) 2004-01-28
AU2002242894B2 (en) 2008-08-21
ZA200407460B (en) 2009-09-30
TR200700134T1 (tr) 2007-02-21
ZA200307478B (en) 2009-04-29
ATE416185T1 (de) 2008-12-15
WO2002079221A2 (en) 2002-10-10
EP1383787B1 (en) 2008-12-03
CN1678325A (zh) 2005-10-05
BR0208533A (pt) 2004-04-20
MXPA03008800A (es) 2004-10-15
GB0107822D0 (en) 2001-05-23
IL158115A0 (en) 2004-03-28
RU2311423C2 (ru) 2007-11-27
AR033079A1 (es) 2003-12-03
PL364825A1 (pl) 2004-12-27
NO20034364D0 (no) 2003-09-29
KR20040007479A (ko) 2004-01-24
RU2003131883A (ru) 2005-05-10

Similar Documents

Publication Publication Date Title
UA78696C2 (en) Novel compounds of sapogenin derivatives, use thereof and composition
AU2002242894A1 (en) Sapogenin derivatives, their synthesis and use
US4235893A (en) Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
RU2325396C2 (ru) Производные 5бета-сапогенина и псевдосапогенина и их применение при лечении деменции
CA2725008C (en) Non-hormonal steroid modulators of nf-.kappa.b for treatment of disease
WO2012106393A2 (en) Withanolide isolated from physalis longifolia and analogs and methods of use thereof
US20190002492A1 (en) Derivatives of allopregnanolone and of epiallopregnanolone and uses thereof for treating a neuropathological condition
JP2013532662A (ja) プロテアソーム活性を向上させる三環系化合物
CN104910238A (zh) 一类五环三萜类化合物及其在制备治疗阿尔兹海默病的药物中的用途
WO2011059969A2 (en) Mammalian metabolites of steroids
CA3091021A1 (en) Derivatives of sobetirome
AU2004222540A1 (en) Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof
WO2017120355A1 (en) Dihydroquinolines and uses thereof
US10464967B2 (en) Non-hormonal steroid modulators of NF-κβ for treatment of disease
AU2011352378B2 (en) Oxidosqualene cyclase as a protein target for anticancer therapeutics
WO1994012527A1 (en) Therapeutic compounds suitable for the treatment of diseases connected with glutathione deficiency, process for their preparation, and pharmaceutical compositions containing same
JP2022527327A (ja) てんかんおよび発作疾患の治療のための３α５β－神経活性ステロイド
NZ540712A (en) Steroidal sapogenin derivatives, their synthesis and their use in the treatment of cognitive dysfunction
US20240270786A1 (en) Steroid compounds
US3818055A (en) 17-(aralkylaminoalkyl)androstan-3b-ols, 5 derivatives thereof, ethers and esters corresponding
EP0085283A1 (en) Pyroglutamyl-tryptophan derivatives, process for their preparation and their therapeutic applications
Buisson Bordet et a
HK1092159A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
PL203412B1 (pl) Zastosowanie pochodnych sapogeniny
AU2063700A (en) Benzopyran-containing compounds and method for their use